Repositioning Candidate Details
| Candidate ID: | R0183 |
| Source ID: | DB00540 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Nortriptyline |
| Synonyms: | 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Δ5,γ-propylamine; 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; Demethylamitriptyline; Desmethylamitriptyline |
| Molecular Formula: | C19H21N |
| SMILES: | CNCCC=C1C2=CC=CC=C2CCC2=CC=CC=C12 |
| Structure: |
|
| DrugBank Description: | Nortriptyline hydrochloride, the active metabolite of , is a tricyclic antidepressant (TCA). It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions. |
| CAS Number: | 72-69-5 |
| Molecular Weight: | 263.3767 |
| DrugBank Indication: | Nortriptyline is indicated for the relief of the symptoms of major depressive disorder (MDD). Some off-label uses for this drug include treatment of chronic pain, myofascial pain, neuralgia, and irritable bowel syndrome. |
| DrugBank Pharmacology: | Nortriptyline exerts antidepressant effects likely by inhibiting the reuptake of serotonin and norepinephrine at neuronal cell membranes. It also exerts antimuscarinic effects through its actions on the acetylcholine receptor. |
| DrugBank MoA: | Though prescribing information does not identify a specific mechanism of action for nortriptyline, is believed that nortriptyline either inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at the level of the beta-adrenergic receptors. It displays a more selective reuptake inhibition for noradrenaline, which may explain increased symptom improvement after nortriptyline therapy. Tricyclic antidepressants do not inhibit monoamine oxidase nor do they affect dopamine reuptake. As with other tricyclics, nortriptyline displays affinity for other receptors including mACh receptors, histamine receptors, 5-HT receptors, in addition to other receptors. |
| Targets: | Sodium-dependent noradrenaline transporter inhibitor; Sodium-dependent serotonin transporter inhibitor; 5-hydroxytryptamine receptor 2A antagonist; 5-hydroxytryptamine receptor 1A antagonist; Histamine H1 receptor antagonist; Alpha-1A adrenergic receptor antagonist; Alpha-1D adrenergic receptor antagonist; 5-hydroxytryptamine receptor 2C antagonist&downregulator; Alpha-1B adrenergic receptor antagonist; Alpha-2 adrenergic receptors antagonist; Beta adrenergic receptor antagonist; Dopamine D2 receptor antagonist; Sigma receptor binder; 5-hydroxytryptamine receptor 1C antagonist; Muscarinic acetylcholine receptor antagonist |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|